Have questions for our experts or want more information?
Contact Us Today
Webinar Overview
Cell therapy developers face a critical choice when selecting the right starting material. This choice can dramatically impact manufacturing efficiency, scalability, and patient access.
In this webinar, we’ll explore how purified and cryopreserved cell populations such as GMP-compliant PBMCs and isolated T cells streamline logistics, reduce variability, and enhance transduction efficiency in CAR-T production. Learn how these materials help mitigate risks, including unwanted cell expansion, and support consistent, high-quality outcomes in both autologous and allogeneic therapies.
What you’ll gain from viewing:
- Insights into cryopreserved cellular starting materials and their manufacturing advantages
- Best practices for collecting and processing GMP-compliant PBMCs
- Data-driven results from using isolated T cells or PBMCs in CAR-T development
- Strategies to improve manufacturing efficiency with purified cell populations
Whether you're optimizing existing workflows or scaling up for clinical production, this presentation will help you make informed decisions that increase the probability of success.
Webinar Presenters
Wassim Basheer, PhD
Senior Product Manager - Cell Solutions
Charles River
Alex Sargent, PhD
Director, Process Development, Cell Therapy CDMO Services
Charles River